5 April 2022

High quality PD-L1 recombinant antibody for IHC assay

GeneTex has worked with independent labs to validate the quality of its PD-L1 recombinant rabbit monoclonal antibodies (GTX636033 and GTX635975). The data demonstrates the antibody’s superior signal-to-noise ratio.

Programmed death ligand 1 (PD-L1) is expressed on various cancer cells and triggers immunosuppressive signals through binding to the programmed cell death protein 1 (PD-1) found on effector T cells. This interaction diminishes immune system attack on malignant cells. Blockade of PD-L1/PD-1 association with PD-L1 or PD-1 monoclonal antibodies is a clinically productive mode of immunotherapy against multiple cancers.

GeneTex has augmented its expanding catalog of rabbit recombinant antibodies with two new reagents directed against programmed death-ligand 1 (PD-L1). Both GTX636033 and GTX635975 generate robust signals on western blot that outperform a competitor’s top product. In addition, GTX635975 is also validated for immunohistochemistry and was demonstrated to be specific for PD-L1 with no cross-reactivity to PD-L2. These antibodies join GeneTex’s well-cited PD-L1 rabbit polyclonal antibody (GTX104763) as the best characterized of a series of GeneTex reagents for the study of this clinically important immune checkpoint inhibitor.

Product nameClonalityAppliciations
PD-L1 antibody [HL1041] (GTX635975)Rb mAbWB, IHC-P
PD-L1 antibody [HL1056] (GTX636033)Rb mAbWB
PD-L1 antibody (GTX104763)Rb pAbWB, ICC/IF, IHC-P, IHC-Fr

High quality PD-L1 recombinant antibody for IHC assay

Related articles

Newsletter for researchers

We gladly support you by keeping you updated on our latest products and the developments around our services.

we Connect you
Need help? Contact our technical support